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A B S T R A C T   
Purpose: To investigate the effects of sequential therapy with monthly intravenous ibandronate on bone mineral 
density (BMD) and microstructure in patients with primary osteoporosis who received teriparatide treatment. 
Methods: Sixty-six patients with primary osteoporosis who had undergone teriparatide treatment for more than 
12 months (mean 18.6 months) received sequential therapy with 1 mg/month intravenous ibandronate for 12 
months. The patients were evaluated using dual-energy X-ray absorptiometry (DXA), quantitative ultrasound, 
bone turnover markers, and high-resolution peripheral quantitative computed tomography (HR-pQCT) at 
baseline and 6 and 12 months after beginning administration. 
Results: At 12 months after beginning sequential therapy, the bone resorption marker, tartrate-resistant acid 
phosphatase-5b, decreased by 39.5%, with 82.3% of the patients exhibiting levels within the normal limit. DXA 
revealed that the BMD of the lumbar spine increased by 3.2%, with 79.0% of the patients exhibiting a response, 
and 40.3% experiencing an increase in BMD over 5%. HR-pQCT revealed that the cortical thickness of the distal 
tibia was increased by 2.6%. The cortical area increased by 2.5%, and the buckling ratio (an index of cortical 
instability) decreased by 2.5%. Most parameters of the trabecular bone showed no significant changes. These 
changes in the cortical bone were observed in both the distal radius and tibia and appeared beginning 6 months 
after treatment initiation. 
Conclusions: Sequential therapy with monthly intravenous ibandronate increased the BMD and improved the 
cortical bone microstructure of osteoporotic patients who had undergone teriparatide treatment.   
1. Introduction 
Teriparatide is now commonly used for patients with severe osteo-
porosis [1–4]. However, when osteoporosis treatment is discontinued 
after completion of teriparatide, the increased bone is not maintained 
but decreases. Therefore, sequential therapy with a bone resorption 
inhibitor is recommended [5–12]. 
Although denosumab possesses strong osteoclastic inhibitory effects, 
because of the risk of intense acceleration of bone resorption after 
discontinuation [13–15], caution is required, especially in elderly 
* Corresponding author at: 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. 
E-mail address: kohchiba@estate.ocn.ne.jp (K. Chiba).  
Contents lists available at ScienceDirect 
Bone 
journal homepage: www.elsevier.com/locate/bone 
https://doi.org/10.1016/j.bone.2020.115770 
Received 19 August 2020; Received in revised form 14 November 2020; Accepted 22 November 2020   
Bone 144 (2021) 115770
2
patients for whom reliable follow-up is challenging. 
In contrast, bisphosphonates are long-acting drugs that retain their 
effects after treatment is discontinued [16,17]. Accordingly, switching 
to a bisphosphonate following teriparatide treatment has become a 
viable option [5–7,10,12]. 
Oral bisphosphonates for elderly patients are effective, but prob-
lematic in terms of compliance, polypharmacy, and a concern with 
sustainability [18]. Once-yearly intravenous administration of zoledro-
nate may induce renal damage [19]. 
In North America and Europe, ibandronate, a nitrogen-containing 
bisphosphonate, is approved for oral use of 150 mg monthly and 
intravenous preparations of 3 mg once every 3 months [20]. In Japan, 
monthly intravenous preparations of 1 mg are approved and used for 
many elderly patients due to the reliable bioavailability and minimal 
adverse reactions [21–26]. To treat elderly patients with severe osteo-
porosis, sequential administration of teriparatide followed by ibandro-
nate is frequently performed. However, evidence is not sufficient 
regarding the efficacy of this regimen. 
High-resolution peripheral quantitative computed tomography (HR- 
pQCT) has the highest resolution (voxel size: 60.7 μm) among all 
available clinical CT methods and enables non-invasive analysis of 
changes in bone microstructure in osteoporotic patients [27–29]. In 
2014, second-generation HR-pQCT technology was developed, 
providing faster scan times and higher resolution [30,31]. To date, no 
previous studies have used HR-pQCT to analyze the effects of monthly 
intravenous ibandronate [32]. 
The purpose of this study is to investigate how sequential therapy 
with monthly intravenous ibandronate affects the bone mineral density 
(BMD) and microstructure in patients with primary osteoporosis who 
have undergone teriparatide treatment. 
2. Methods 
2.1. Study design 
This study examined the effects of monthly intravenous injections of 
ibandronate (Bonviva Syringes for Intravenous Injection, Chugai Phar-
maceutical Co.) for 12 months for osteoporotic patients who had un-
dergone teriparatide treatment. The study was conducted as a single- 
arm, open-label, multi-center joint trial (Fig. 1) (Effects of MOnthly 
intravenous ibaNdronate on bone mineral density and MicrostrUcturE in 
patieNts with primary osteoporosis after Teriparatide treatment: MON-
UMENT study). This study was approved by the Nagasaki University 
Clinical Research Review Board and was registered in the Japan Registry 
of Clinical Trials (jRCT) (jRCTs071180086). 
2.2. Subjects 
The study involved patients with primary osteoporosis who had 
received teriparatide treatment for more than 12 months. The inclusion 
criteria were age of 55 years or older, female sex, and a compliance rate 
of at least 75% for teriparatide treatment. The exclusion criteria were 
serious cardiac disease, serious hepatic disease, serious renal disease, 
active malignant tumor, endocrine metabolic disease affecting bone 
metabolism, secondary osteoporosis (steroids, rheumatoid arthritis, 
immobility, etc.), previous history of steroid use at 5 mg and above for 3 
months or longer, previous history of drug use affecting bone meta-
bolism, oversensitivity to bisphosphonate preparations, hypocalcemia, 
and three or more vertebral fractures in the first to fourth lumbar 
vertebrae. 
2.3. Intervention 
Within 8 weeks after the final use of teriparatide, the subjects started 
receiving monthly intravenous ibandronate (Bonviva® Intravenous In-
jection 1 mg Syringe, Chugai Pharmaceutical Co., Ltd.) for 12 months 
and a medical compound of calcium (610 mg/day), natural vitamin D 
(400 IU/day), and magnesium (30 mg/day) (New Calcichew, Takeda 
Pharmaceutical Co.). A notebook was handed to each subject to keep 
track of oral ingestion every morning to confirm drug compliance. 
During the administration period, information on adverse events was 
collected. 
2.4. Dual-energy X-ray absorptiometry (DXA) and quantitative 
ultrasound (QUS) 
At baseline and 6 and 12 months after beginning administration, 
bone density was assessed with DXA and QUS. Using DXA (Lunar 
Prodigy Advance, GE Lunar, Madison, WI), the areal bone mineral 
density (aBMD) and T-scores of the lumbar spine (L1–4), proximal femur 
(total hip and femoral neck on both sides), and radius (radius 1/3) were 
measured. Measurements of the lumbar spine were strictly excluded if a 
high aBMD due to degenerative changes and fractures was confirmed in 
images. The speed of sound (SOS) in the calcaneus was measured using 
QUS (CM200, Furuno Electric Co., Ltd., Nishinomiya, Japan). 
Regarding reproducibility, root-mean-square coefficient of variation 
(RMS%CV) was 0.99% for aBMD of the lumbar spine (L1–4), 0.42% for 
the total hip, 0.76% for the femoral neck, and 0.48% for the SOS of the 
calcaneus. 
2.5. Bone turnover markers 
At baseline and 6 and 12 months after beginning administration, 
bone metabolism was evaluated with the bone resorption marker, 
tartrate-resistant acid phosphatase-5b (TRACP-5b) and the bone for-
mation marker, total type I procollagen-N-propeptide (total P1NP). In 
addition, general biochemical levels of corrected calcium, phosphorus, 
and intact parathyroid hormone were also examined. At baseline only, 
levels of 25-hydroxyvitamin D (25(OH) vitamin D) and pentosidine were 
measured. 
Fig. 1. Study protocol of the MONUMENT study.  
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2.6. HR-pQCT scan 
At baseline and 6 and 12 months after beginning administration, the 
volumetric bone mineral density (vBMD), bone microstructure, and 
estimated bone strength were assessed with HR-pQCT. With the non- 
dominant forearm and lower leg of each patient fixed with a special-
ized cast, the distal radius and tibia were scanned with second- 
generation HR-pQCT (XtremeCT II, SCANCO Medical AG, Brüttisellen, 
Switzerland). Based on the guidelines for the HR-pQCT assessments, the 
scanned regions were set at a 10.2-mm width of the distal radius 4% 
proximal of the forearm length from the hand joint and a 10.2-mm width 
of the distal tibia 7.3% proximal of the lower leg length from the 
talocrural joint [33,34]. The scan conditions were as follows: tube 
voltage: 68 kVp; tube current: 1470 μA; integration time: 4.3 ms; 
number of projections: 900; field of view: 140 mm; matrix: 2304 × 2304; 
voxel size: 60.7 μm; number of images: 168; scan time: 2.0 min; exposed 
dose: CTDIvol 10.8 mGy, DLP 11.0 mGy⋅cm; and effective dose: 5 μSv. 
2.7. Bone microstructure analysis 
Three-dimensional registration of the HR-pQCT images was per-
formed for the datasets at baseline and 6 and 12 months after beginning 
administration. vBMD and bone microstructures were analyzed for the 
common domain of the three datasets (TRI/3D-BON, Ratoc System En-
gineering Co., Ltd.) [35]. Measurement items were divided into the 
following three categories [36]: 
1) Trabecular bone: Trabecular volumetric bone mineral density (Tb. 
vBMD, mg/cm3); trabecular bone volume fraction (BV/TV, %); trabec-
ular thickness (Tb.Th, mm); trabecular number (Tb.N, 1/mm); trabec-
ular separation (Tb.Sp, mm); structure model index (SMI): an index for 
quantifying the trabecular shape, whether it is plate-shaped (SMI = 0) or 
rod-shaped (SMI = 3); connectivity density (Conn.D): an index for 
quantifying trabecular connection; and degree of anisotropy (DA): an 
index for quantifying the trabecular direction. 
2) Cortical bone: Cortical volumetric bone mineral density (Ct. 
vBMD, mg/cm3); cortical volumetric tissue mineral density (Ct.vTMD, 
mg/cm3); cortical porosity (Ct.Po, %); cortical perimeter (Ct.Pm, mm); 
cortical area (Ct.Ar, mm2); cortical thickness (Ct.Th, mm); minimum 
cortical thickness (Ct.Th.Min, mm); and buckling ratio (BR): an index for 
resistance to buckling calculated from the maximum distance from the 
bone axis to the cortical bone and the cortical thickness. 
3) Total bone: Total volumetric bone mineral density (Tt.vBMD, mg/ 
cm3); stiffness (kN/mm); and failure load (FL, kN). 
vBMD values were converted from the X-ray attenuation values using 
a regression line created from phantom images. Bone microstructure 
analysis was performed on binarized images with a threshold of 320 mg/ 
cm3 for trabecular bone and 450 mg/cm3 for cortical bone. Tb.Th, Tb.Sp, 
and Ct.Th were directly measured [37]. 
Stiffness and failure load were analyzed using the finite element 
method (IPL, SCANCO Medical AG). With a Young’s modulus of 10 GPa 
and a Poisson ratio of 0.3, bone stiffness when a load is applied to the 
bone axis direction was predicted. Failure was defined as more than 
2.0% of all voxels becoming strained by at least 0.7%. 
Regarding reproducibility, RMS%CV at the radius and tibia, 
respectively, were: 1.86% and 1.48% for Tb.vBMD, 1.42% and 1.11% 
for BV/TV, 0.94% and 0.84% for Tb.Th, 1.75% and 2.45% for Tb.N, 
2.31% and 3.27% for Tb.Sp, 3.25% and 5.20% for SMI, 5.76% and 
5.79% for Conn.D, 3.56% and 2.05% for DA, 0.59% and 0.57% for Ct. 
vBMD, 0.59% and 0.57% for Ct.vTMD, 6.08% and 6.02% for Ct.Po, 
0.10% and 0.10% for Ct.Pm, 0.92% and 1.34% for Ct.Ar, 0.99% and 
1.38% for Ct.Th, 1.73% and 1.32% for Ct.Th.Min, 1.02% and 1.50% for 
BR, and 0.90% and 1.01% for Tt.vBMD. 
2.8. Endpoints 
The primary endpoint of this study was the percent change in DXA- 
measured aBMD values in the lumbar spine (L1–4) from baseline to 12 
months after the first administration. The percent change at 12 months 
was calculated as a proportion of the change: measurement at 12 months 
– measurement at baseline/measurement at baseline The secondary 
endpoints were the percent change of all other evaluation items from 
baseline to 6 and 12 months after beginning administration. 
2.9. Statistical analysis 
The sample size was determined based on the result from our power 
analysis. Referring to a previous report [5], we postulated that the mean 
and standard deviation of the standardized change in aBMD at 12 
months from the switch in medication to a bisphosphonate from ter-
iparatide are 2.5% (5.5%). According to this assumption, we calculated 
that 53 was the minimum sample size with a statistical power over 80% 
to detect a standardized change at 12 months >0 using the Student’s t- 
test with the alpha of 0.05 (two-sided). Further, 13 patients were added 
based on the estimation of a 20% dropout rate. Therefore, we decided to 
recruit 66 patients as subjects in our study. 
For the primary analysis, we used the Student’s t-test to test the null 
hypothesis that the mean of the primary endpoint is 0 on the full analysis 
set (FAS). The FAS consisted of all subjects who received at least one 
protocol treatment and who had results of aBMD measurement at 
baseline and month 6, month 12, or both. Another analysis set was the 
per protocol set (PPS), which consisted of subjects in the FAS who 
received administration of ibandronate over 80% of the planned pro-
tocol treatment, who showed adherence to treatment with the medical 
compound of calcium, natural vitamin D, and magnesium over 60% for 
every month during the observation period, who had measurement re-
sults for aBMD for all time points (baseline, 6 and 12 months), and who 
had no major protocol deviations that could affect the efficacy assess-
ment. As for FAS, missingness in the measurement results at 12 months 
was complemented by addition of the result at 6 months and the least 
change between 6 and 12 months among the FAS. Also, missingness in 
the measurement results at 6 months was complemented by the arith-
metic mean of the results at baseline and 12 months for the FAS. The 
same analysis on the PPS was conducted for supportive purposes. 
The measured values, changes, and percent change were summa-
rized by the arithmetic mean, standard deviations, 95% confidence in-
tervals (95% CI), and p-values from the two-sided Student’s t-test. The 




As shown in Fig. 2, 66 patients were enrolled in this study. Overall, 
three patients withdrew within 6 months after beginning administra-
tion, and one patient discontinued within 12 months, resulting in a 
dropout rate of 6.1%. In the FAS, one patient had no measurement re-
sults at 12 months, and the missingness was complemented as described 
in the statistical analysis section. 
As listed in Table 1, the analysis subjects (63 in the FAS) had a mean 
age of 77.3 years. They were mostly elderly, with 69.8% over the age of 
75 years. They were small women with a mean height of 147.7 cm and 
body mass index of 22.6 kg/m2. 
Among the participants, 61.9% had a previous history of fragility 
vertebral fractures (11 thoracic, 15 lumbar, and 13 thoracolumbar 
vertebrae) and received teriparatide treatment for an average of 18.6 
months. The median DXA T-scores were − 2.7 for the lumbar spine, − 2.0 
for the total hip, and − 2.5 for the femoral neck; 74.6% of the patients 
were diagnosed with osteoporosis (T-score <− 2.5). The median TRACP- 
5b value was 469 mU/dL, and that of total P1NP was 62.5 μg/L. The 
level of 25(OH) vitamin D was 12.3 ng/mL, indicating vitamin D 
deficiency. 
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3.2. DXA and QUS 
As listed in Table 2, the aBMD in the lumbar spine increased by 2.2% 
after 6 months and 3.2% (95% CI: 1.8 to 4.6%) after 12 months (p <
0.0001) (primary endpoint). Fig. 3 shows that 79.0% of the patients 
were responders, and 40.3% exhibited an increase of at least 5% after 1 
year. The aBMD of the total hip increased by 1.1% after 6 months and 
1.2% after 12 months, with 80.6% of the patients being responders. The 
radial 1/3 aBMD and calcaneal SOS values exhibited minimal changes. 
We confirmed that the effect of complementation for missingness 
(described in the statistical analysis section) was trivial by checking the 
mean after removal of the complemented data. 
3.3. Bone turnover markers 
As listed in Table 2, the TRACP-5b decreased by 43.4% after 6 
months and 39.5% after 12 months. Fig. 4 shows that 82.3% of the 
patients exhibited levels of TRACP-5b within the normal limit after 12 
months. Likewise, the total P1NP decreased by 58.9% after 6 months 
and by 60.2% after 12 months; 73.8% of the patients exhibited levels of 
P1NP within the normal limit after 12 months. 
3.4. HR-pQCT 
As listed in Tables 3 and 4 and shown in Fig. 5, no significant changes 
were observed in most of the trabecular bone parameters except for 
decreased Tb.vBMD in the tibia. 
In the cortical bone, Ct.vBMD and the cortical porosity did not 
change significantly. In the tibia, Ct.Th increased by 2.8% after 6 months 
and by 2.6% after 12 months. Consequently, Ct.Ar also increased by 
2.7% after 6 months and by 2.5% after 12 months. Meanwhile, BR 
decreased by 2.8% after 6 months and by 2.5% after 12 months, indi-
cating an improvement in cortical stability. Similar changes were 
observed in the radius. As shown in Fig. 5B, 82.3% and 93.4% of the 
patients exhibited increased Ct.Th in the radius and tibia, respectively. 
An increase over 2% was noted in 38.7% and 54.1% of the patients, 
respectively. No significant differences were found in Tt.vBMD and 
estimated bone strength in the radius and tibia. 
Fig. 6 shows images of bone microstructural changes in a responder 
patient. 3D images show bone formation (yellow) on the surface of the 
endocortical and trabecular bone (Fig. 6E and F). In this 3D registration 
method, bone formation is defined as voxels with a mineral density 
above 450 mg/cm3 of the threshold at 12 months due to an increase in 
Fig. 2. Consort diagram of the MONUMENT study.  
Table 1 
Background data of the patients included for the analysis (n = 63).    
Study population (n 
= 63) 
Age (years) 77.3 ± 7.3 (58, 90) 
Age > 75 years (n, %) 44 (69.8) 
Height (cm) 147.7 ± 6.6 (131.7, 
160.7) 
Weight (kg) 49.3 ± 7.6 (32.0, 
70.0) 
BMI (kg/m2) 22.6 ± 2.8 (15.2, 
30.2) 
History of fragility 
fracture 
Vertebra (n, %) 39 (61.9) 
Proximal femur (n, %) 5 (7.9) 
Distal radius (n, %) 9 (14.3) 
Others (n, %) 2 (3.2) 




(months) 18.6 ± 4.9 (12, 24) 
FRAX Major OP fracture (%) 29.0 (22.0, 36.0) 
Hip fracture (%) 11.0 (7.5, 18.5) 
DXA 
T-score 
Lumbar spine  − 2.7 (− 3.4, − 1.8) 
Total hip  − 2.0 (− 2.5, − 1.4) 
Femoral neck  − 2.5 (− 3.1, − 2.0) 
Radius 1/3  − 3.8 (− 4.6, − 3.2) 
Osteoporosis (n, %) 47 (74.6) 
Osteopenia (n, %) 13 (20.6) 
Blood test TRACP-5b (mU/dL) 469 (390.5, 617.5) 
total P1NP (μg/L) 62.5 (42.0, 76.3) 
25(OH) vitamin D (ng/mL) 
(nmol/L) 
12.3 (9.4, 17.3) 
30.8 (23.5, 43.3) 
Pentosidine (pmol/ 
mL) 
33.1 (25.8, 41.6) 
Corrected Calcium (mg/dL) 9.5 (9.3, 9.8) 
Phosphate (mg/dL) 3.4 (3.0, 3.8) 
intact PTH (pg/mL) 52.4 (36.6, 67.9) 
BMI: body mass index, OP: osteoporosis, DXA: dual-energy x-ray absorptiome-
try, TRACP-5b: tartrate-resistant acid phosphatase 5b, P1NP: Procollagen type 1 
N propeptide, 25(OH) vitamin D: 25-hydroxyvitamin D, PTH: parathyoid hor-
mone. 
Mean ± SD (Min, Max), Number (%), Median (25%, 75%). 
Table 2 
Changes in aBMD measured by DXA, SOS measured by QUS, and bone turnover 




(n = 63) 
12 months 









































0.6 ± 4.6 0.9 ± 6.0 





0.0 ± 0.8 

















DXA: dual-energy x-ray absorptiometry, aBMD: areal bone mineral density, 
QUS: quantitative ultrasound, SOS: speed of sound, BTM: bone turnover maker, 
TRACP-5b: tartrate-resistant acid phosphatase 5b, P1NP: Procollagen type 1 N 
propeptide. 
Median (25%, 75%), Mean ± SD, * p < 0.01, ** p < 0.001 vs baseline. Bold font 
indicates significant differences. 
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calcification. Therefore, this case shows that new bone on the endo-
cortical and trabecular surface that was generated by teriparatide 
treatment was further calcified by sequential therapy with ibandronate 
and was eventually recognized as bone. 
3.5. Adverse events 
Two patients withdrew because of adverse events (Fig. 2). One had a 
history of angina pectoris and dropped out when the disease recurred. 
The other developed a fever of unknown origin and general pain and was 
consequently excluded. 
4. Discussion 
In this study, we investigated how 12-month sequential therapy with 
intravenous ibandronate (1 mg/month) affected BMD and microstruc-
ture of patients with primary osteoporosis who had undergone ter-
iparatide treatment for more than 12 months. 
4.1. Bone turnover markers 
The bone turnover markers showed a state of high bone turnover at 
baseline, due to the effects of teriparatide treatment (Table 1). Six 
months after switching to ibandronate, the bone turnover markers 
rapidly declined (Table 2). Contrary to the common belief that 
bisphosphonates induce non-physiological suppression of bone meta-
bolism, the majority of the patients exhibited levels within the normal 
limit (Fig. 4). 
4.2. DXA 
This study confirmed that ibandronate has the effect of adding to 
aBMD (lumbar spine 3.2%, total hip 1.2%, femoral neck 1.3%) after 
teriparatide treatment (Table 2, Fig. 3). Several previous studies have 
been conducted with sequential therapy with bisphosphonates, deno-
sumab, and raloxifene after teriparatide [5–12,38–43]. 
Niimi et al. reported that 12 months of sequential therapy with oral 
alendronate (35 mg/week) after 24 months of teriparatide increased 
aBMD in the lumbar spine by 1.3% and femoral neck by 0.7% in 100 
patients (mean 78 years) [41]. Ebina et al. reported that 12 months of 
sequential therapy with oral bisphosphonates (alendronate 35 mg/week 
n = 19, risedronate 17.5 mg/week n = 12, minodronate 50 mg/month n 
= 5) after 24 months of teriparatide increased aBMD in the lumbar spine 
by 2.6%, total hip by 1.1%, and femoral neck by 1.4% in 36 patients 
(mean 73.5 years) [39]. Monthly intravenous ibandronate may have 
equivalent or better effects than oral bisphosphonates. 
Burkard et al. reported that 24 months of zoledronic acid after 24 
Fig. 3. Cumulative distribution of the change in aBMD of the lumbar spine and 
total hip after sequential therapy with ibandronate. In the lumbar spine, 79.0% 
of the patients were responders, and 40.3% of the patients showed an increase 
of over 5% in 12 months. In the total hip, 80.6% of the patients were re-
sponders, and 33.9% of the patients showed an increase of over 2% in 
12 months. 
Fig. 4. Cumulative distribution of the values of TRACP-5b and total P1NP 
before and after sequential therapy with ibandronate. The ranges of the normal 
limit are depicted with dashed lines. Among the patients, 82.3% (TRACP-5b) 
and 73.8% (total P1NP) were within the normal limit in 12 months. 
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months of teriparatide resulted in a 1.8% increase in aBMD in the 
lumbar spine and a 1.1% decrease in the femoral neck in 20 patients 
(mean 65.8 years) [12]. In the same study, 24 months of denosumab 
showed an increase in aBMD in the lumbar spine by 5.7% and femoral 
neck by 4.9% in 26 patients (mean 72.4 years). Although these results 
cannot be directly compared with the results in this study because the 
periods of sequential therapy were different (24 vs. 12 months), monthly 
intravenous ibandronate may have a higher effect on aBMD than zole-
dronic acid and a lower effect than denosumab. 
Eastell et al. reported that 12 months of sequential therapy with 
raloxifene (60 mg/day) after 12 months of teriparatide resulted in a 
0.3% decrease in aBMD in the lumbar spine and a 1.5% increase in 
aBMD in the femoral neck in 97 women (mean 69.4 years) [9]. Adami 
et al. reported that 12 months of sequential therapy with raloxifene (60 
mg/day) after 12 months of teriparatide resulted in a 1.2% decrease in 
aBMD in the lumbar spine and a 2.3% increase in aBMD in the femoral 
neck in 157 women (mean 66.7 years) [8]. Although these results cannot 
be directly compared with the results in this study because the periods of 
the teriparatide treatment were different (12 vs. 19 months), monthly 
intravenous ibandronate may have a better effect on aBMD than ralox-
ifene in the lumbar spine. 
Compared to many previous studies, this study consisted of elderly 
Table 3 
Changes in volumetric bone mineral density, bone microstructure, and esti-
mated bone strength at distal radius.  
Distal radius Baseline (n 
= 63) 
6 months 
(n = 63) 
12 months 
(n = 62) 
Value Change (%) Change (%) 




− 0.3 ± 2.4 − 0.4 ± 2.7 
BV/TV (%) 10.5 (8.1, 
13.0) 
− 0.1 ± 2.9 0.2 ± 3.5 
Tb.Th (μm) 197.3 
(185.9, 
204.4) 
0.0 ± 1.4 0.0 ± 1.8 
Tb.N (/mm) 1.05 (0.94, 
1.18) 
1.0 ± 4.2 1.7 ± 5.5 
Tb.Sp (μm) 755.0 
(661.6, 
874.8) 
− 1.0 ± 5.1 − 1.7 ± 6.4 
SMI  2.35 (2.17, 
2.48) 
0.5 ± 2.6 0.5 ± 3.7 
Conn.D  1.22 (0.77, 
1.70) 
− 0.4 ± 8.0 0.5 ± 8.4 
DA  1.79 (1.68, 
1.92) 
0.1 ± 6.1 0.0 ± 5.3 











− 0.3 ± 1.4 − 0.1 ± 1.8 
Ct.Po (%) 0.98 (0.82, 
1.37) 
0.7 ± 16.2 1.9 ± 17.1 
Ct.Pm (mm) 65.1 (62.3, 
68.8) 
0.0 ± 0.2 − 0.1 ± 0.2 
Ct.Ar (mm2) 36.9 (33.6, 
41.4) 
1.7 ± 2.2** 1.4 ± 2.7** 
Ct.Th (μm) 613.3 
(540.1, 
687.3) 






1.5 ± 1.9** 1.4 ± 2.6** 
















1.2 ± 6.0 0.7 ± 7.6 
Failure 
load 
(kN) 1.71 (1.46, 
2.13) 
1.5 ± 7.2 1.2 ± 9.0 
Tb.vBMD: trabecular volumetric bone mineral density, BV/TV: trabecular bone 
volume fraction, Tb.Th: trabecular thickness, Tb.N: trabecular number, Tb.Sp: 
trabecular separation, SMI: structure model index, Conn.D: connectivity density, 
DA: degree of anisotropy, Ct.vBMD: cortical volumetric bone mineral density, 
Ct.vTMD: cortical volumetric tissue mineral density, Ct.Po: cortical porosity, Ct. 
Pm: cortical perimeter, Ct.Ar: cortical area, Ct.Th: cortical thickness, Ct.Th.Min: 
minimum cortical thickness, BR: buckling ratio, Tt.vBMD: total volumetric bone 
mineral density. 
Median (25%, 75%), Mean ± SD, * p < 0.01, ** p < 0.001 vs baseline. Bold font 
indicates significant differences. 
Table 4 
Changes in volumetric bone mineral density, bone microstructure, and esti-
mated bone strength at distal tibia.  
Distal tibia Baseline (n 
= 63) 
6 months 
(n = 63) 
12 months 
(n = 62) 
Value Change (%) Change (%) 







− 0.9 ± 2.4* 
BV/TV (%) 17.0 (13.1, 
19.6) 
− 0.1 ± 2.0 − 0.2 ± 2.7 
Tb.Th (μm) 210.5 
(199.8, 
226.0) 
− 0.1 ± 1.1 0.0 ± 1.3 
Tb.N (/mm) 1.05 (0.96, 
1.14) 
− 0.4 ± 3.1 − 0.9 ± 3.2 
Tb.Sp (μm) 749.9 
(646.6, 
830.4) 
0.8 ± 4.0 1.4 ± 4.5 
SMI  1.88 (1.63, 
2.04) 
− 1.3 ± 4.9 − 2.0 ± 6.0 
Conn.D  2.25 (1.82, 
2.88) 
− 1.7 ± 5.8 − 2.6 ± 6.8* 
DA  1.98 (1.89, 
2.05) 
0.6 ± 2.9 0.7 ± 3.6 











0.3 ± 1.8 0.3 ± 2.8 




− 1.6 ± 12.3 




− 0.1 ± 0.2* 
Ct.Ar (mm2) 71.2 (64.5, 
77.4) 
2.7 ± 2.2** 2.5 ± 2.3** 
Ct.Th (μm) 780.1 
(719.3, 
862.0) 






1.8 ± 1.9** 1.6 ± 1.9** 
















1.1 ± 3.6 0.5 ± 4.9 
Failure 
load 
(kN) 5.86 (4.91, 
6.30) 
1.1 ± 3.6 0.5 ± 4.7 
Tb.vBMD: trabecular volumetric bone mineral density, BV/TV: trabecular bone 
volume fraction, Tb.Th: trabecular thickness, Tb.N: trabecular number, Tb.Sp: 
trabecular separation, SMI: structure model index, Conn.D: connectivity density, 
DA: degree of anisotropy, Ct.vBMD: cortical volumetric bone mineral density, 
Ct.vTMD: cortical volumetric tissue mineral density, Ct.Po: cortical porosity, Ct. 
Pm: cortical perimeter, Ct.Ar: cortical area, Ct.Th: cortical thickness, Ct.Th.Min: 
minimum cortical thickness, BR: buckling ratio, Tt.vBMD: total volumetric bone 
mineral density. 
Median (25%, 75%), Mean ± SD, * p < 0.01, ** p < 0.001 vs baseline. Bold font 
indicates significant differences. 
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patients who were about 10 years older (mean 77.3 years) than in the 
above studies and with decreased activity due to fragility fractures. 
Simple comparisons of the results are not possible. However, the inci-
dence of vertebral and proximal femoral fractures increases after the age 
of 70, and this study shows real-world results. 
4.3. HR-pQCT 
The cortical thickness (Ct.Th) increased in both the radius and tibia 
(1.5% and 2.6%, respectively) with ibandronate (Tables 3 and 4, 
Fig. 5B). Consequently, an increase in the cortical area (Ct.Ar) and a 
decrease in cortical instability (BR: an index of cortical instability) were 
observed. We also measured the minimum cortical thickness (Ct.Th. 
Min) to evaluate the most fragile part of the whole circumference of the 
cortical bone, and the results indicated significant improvements. These 
effects were greater in the tibia than in the radius, perhaps because the 
tibia is a weight-bearing bone. In contrast, no significant changes were 
noted in the density and porosity of the cortical bone (Ct.vBMD and Ct. 
Po) in this study. Although we initially predicted that the cortical 
porosity induced by teriparatide would be reduced by ibandronate, this 
study yielded no such findings. 
HR-pQCT did not detect significant changes in most trabecular bone 
parameters (Tables 3 and 4). As shown in Fig. 5, the trabecular bone 
showed different changes from patient to patient, with some patients 
maintaining, some increasing, and others decreasing the trabecular 
bone. 
Only one previous report used HR-pQCT to investigate the effects of 
sequential therapy after teriparatide treatment [43]. Leder et al. re-
ported that 24 months of teriparatide followed by 24 months of deno-
sumab increased Ct.Th in the tibia by 4.7% (as read from the graph), and 
Ct.vBMD increased by 3.0% in 27 women (66.1 years). On the other 
hand, Ct.Po and trabecular bone microstructure did not change signifi-
cantly. Although these results cannot be directly compared with the 
results in this study because the average age of the participants was 11 
years younger and the duration of sequential therapy was 12 months 
longer than those of this study, the results seemed to reflect the strong 
bone resorption inhibitory effect of denosumab. 
Three previous reports have described HR-pQCT analysis of the ef-
fects of ibandronate in osteoporotic patients [44–46]. All these studies 
used oral ibandronate (150 mg/month), and one was a randomized 
clinical trial using ibandronate and a placebo. Over a 24-month obser-
vation period, the study showed that ibandronate leads to an increase in 
cortical vBMD [45]. The design of this study differed from that of the 
present study in many ways: younger age (63 vs. 77 years), not osteo-
porotic (Lumbar − 1.4, Femoral neck − 1.5 vs. Lumbar − 2.4, Femoral 
neck − 2.5), use of an oral preparation (oral 150 mg vs. 1 mg i.v.), 
administration period (24 months vs. 12 months), osteoporosis treat-
ment naïve (naïve vs. teriparatide sequential treatment), and use of 
different HR-pQCT devices (XtremeCT vs. XtremeCT II). The remaining 
two reports were a study on patients with glucocorticoid-induced oste-
oporosis (systemic lupus erythematosus) and a study on combined 
therapy with ibandronate and teriparatide (PICS), respectively [44,46]. 
Fig. 5. A Cumulative distribution of the change in trabecular bone volume fraction (BV/TV) in the distal radius and tibia after sequential therapy with ibandronate. 
Among the patients, 52.5% (distal radius) and 42.6% (distal tibia) were responders in 12 months. 
B Cumulative distribution of the change in cortical thickness (Ct.Th) in the distal radius and tibia after sequential therapy with ibandronate. In the distal radius, 
82.3% of the patients were responders, and 38.7% of the patients showed an increase of over 2% in 12 months. In the distal tibia, 93.4% of the patients were 
responders, and 54.1% of the patients showed an increase of over 2% in 12 months. 
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5. Strengths & limitations 
The strength of this study is the fact that the analysis involved 
various parameters, was detailed, used various techniques such as DXA, 
blood testing, HR-pQCT, and a 3D registration method, and tested 
sequential therapy, which is now a critical topic in current osteoporotic 
medical care. 
A limitation of this study was that it was a single-arm study that did 
not involve comparison with an untreated control cohort or cohorts 
treated with other drugs. Another limitation was that this study started 
observations not from the time of initial treatment with teriparatide but 
beginning with the switch to ibandronate. Changes due to teriparatide 
treatment remain unclear. Also, the relatively small sample size may 
have affected the statistical non-significance. Moreover, Vitamin D and 
pentosidine were evaluated at baseline only and were not assessed after 
ibandronate treatment. 
6. Conclusions 
Sequential therapy with monthly intravenous ibandronate following 
teriparatide treatment resulted in a 39.5% decrease in the bone 
resorption marker, TRACP-5b, and a 3.2% increase in the aBMD of the 
lumbar spine in patients with primary osteoporosis. In addition, HR- 
pQCT revealed that cortical thickness increased by 2.6%, and the BR, 
which is an index of cortical instability, decreased by 2.5% in the tibia. 
These results demonstrate the positive effects of sequential therapy with 
Fig. 6. HR-pQCT images of a responder patient following sequential therapy with ibandronate. A 67-year-old woman with vertebral fractures was treated using 
teriparatide 20 μg/day for 24 months followed by ibandronate 1 mg/month for 12 months. 2D images show the increase in bone mineral density at 12 months (B and 
D) compared with baseline (A and C). 3D superimposed images (E and F) clearly show that bone formation has occurred on the surfaces of endocortical and 
trabecular bones. 
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monthly intravenous ibandronate on BMD and cortical bone 
microstructure. 
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